Published in J Clin Invest on December 01, 1986
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Disruption of the subendothelial basement membrane during neutrophil diapedesis in an in vitro construct of a blood vessel wall. J Clin Invest (1989) 1.62
Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest (1988) 1.10
Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin). J Clin Invest (1988) 0.94
Biological properties of human C5a: selected in vitro and in vivo studies. Clin Exp Immunol (1988) 0.80
Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl (1968) 60.35
A method for determining the sedimentation behavior of enzymes: application to protein mixtures. J Biol Chem (1961) 59.20
Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med (1973) 14.88
Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol (1978) 6.04
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
Biologial effects of the human complement fragments C5a and C5ades Arg on neutrophil function. Immunopharmacology (1980) 2.35
Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem (1978) 2.32
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
Micropore filter assay of human granulocyte locomotion: problems and solutions. Clin Immunol Immunopathol (1978) 1.36
Human C5a des Arg increases vascular permeability. J Immunol (1981) 1.28
A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest (1978) 1.28
Demonstration of a specific receptor for human C5a anaphylatoxin on murine macrophages. J Exp Med (1982) 1.28
Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a. Proc Natl Acad Sci U S A (1981) 1.23
Response of human neutrophils to C5a: a role for the oligosaccharide moiety of human C5ades Arg-74 but not of C5a in biologic activity. J Immunol (1981) 1.10
Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide ("cochemotaxin") in normal serum and plasma. J Immunol (1981) 1.01
Isolation and characterization of an acidic chemotactic factor from complement-activated human serum. Clin Immunol Immunopathol (1980) 0.98
The chemokinetic effect of serum albumin. Experientia (1977) 0.98
Chemotactic activity of C5ades Arg: evidence of a requirement for an anionic peptide 'helper factor' and inhibition by a cationic protein in serum from patients with systemic lupus erythematosus. Mol Immunol (1980) 0.97
Partial characterization of in vivo chemotactic activity: comparison to human C5a. J Allergy Clin Immunol (1977) 0.83
Removal or oxidation of surface membrane sialic acid inhibits formyl-peptide-induced polymorphonuclear leukocyte chemotaxis. J Immunol (1985) 0.80
Preservation of C3, C5, and C5a functional activities by a new radiolabeling method; demonstration of C5 products in complement-activated serum. J Immunol (1979) 0.78
Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest (1975) 6.25
Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med (1971) 3.38
Calcium-induced lysozyme secretion from human polymorphonuclear leukocytes. Biochem Biophys Res Commun (1974) 3.24
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
Evidence that the superoxide-generating system of human leukocytes is associated with the cell surface. J Clin Invest (1977) 2.77
Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. J Immunol (1973) 2.66
Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med (1981) 2.63
Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A (1985) 2.38
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med (1994) 2.38
Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg (1983) 2.29
Potassium and amino acid transport in human leukocytes exposed to phagocytic stimuli. J Cell Biol (1974) 2.16
Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol (1997) 2.10
Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum (1981) 2.04
Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol (1974) 2.02
Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. J Immunol (1976) 1.97
Mechanisms of lysosomal enzyme release from human polymorphonuclear leukocytes. Effects of phorbol myristate acetate. J Cell Biol (1975) 1.87
Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem (1979) 1.84
Role of microtubule assembly in lysosomal enzyme secretion from human polymorphonuclear leukocytes. A reevaluation. J Cell Biol (1977) 1.69
Sudden blindness in acute pancreatitis. Possible role of complement-induced retinal leukoembolization. Arch Intern Med (1981) 1.62
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61
Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med (1978) 1.57
A modified method for chemotaxis under agarose. J Immunol Methods (1979) 1.55
Biocompatibility of hemodialysis membranes: evaluation in an ovine model. J Lab Clin Med (1993) 1.46
Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J Biol Chem (1984) 1.44
Enhancement of nitroblue tetrazolium dye reduction by leukocytes exposed to a component of complement in the absence of phagocytosis. J Immunol (1975) 1.43
Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci (1998) 1.43
Influence of divalent cations upon complement-mediated enzyme release from human polymorphonuclear leukocytes. J Immunol (1975) 1.43
Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol (1980) 1.41
An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus. J Clin Invest (1990) 1.41
Gastrointestinal "sterilization" in the treatment of patients with acute leukemia. Cancer (1970) 1.39
Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro. Reduction of lysosomal enzyme release and superoxide anion production. J Exp Med (1977) 1.36
Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med (1982) 1.35
HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol (1989) 1.34
Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol (1985) 1.30
Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest (1998) 1.30
A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest (1978) 1.28
Demonstration of a specific receptor for human C5a anaphylatoxin on murine macrophages. J Exp Med (1982) 1.28
Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis (1984) 1.28
Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J Immunol (1989) 1.27
A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol (1991) 1.26
Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 1.22
Characterization of polymorphic forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 1.21
Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem (2000) 1.20
Co-expression of chemotactic ligand receptors on human peripheral blood monocytes. J Immunol (1987) 1.16
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450. J Clin Invest (1985) 1.15
Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J Clin Invest (1984) 1.14
Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells. J Immunol (1986) 1.13
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids. J Biol Chem (1985) 1.12
Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. J Immunol (1984) 1.11
Response of human neutrophils to C5a: a role for the oligosaccharide moiety of human C5ades Arg-74 but not of C5a in biologic activity. J Immunol (1981) 1.10
Antiinflammatory effects of endotoxin. Inhibition of rabbit polymorphonuclear leukocyte responses to complement (C5)-derived peptides in vivo and in vitro. Am J Pathol (1983) 1.10
Nonphagocytic stimulation of human polymorphonuclear leukocytes: role of the plasma membrane. Semin Hematol (1979) 1.10
Endotoxin-induced selective dysfunction of rabbit polymorphonuclear leukocytes in response to endogenous chemotactic factors. Infect Immun (1985) 1.09
Quantitative comparisons of neutrophil chemotaxis in four animal species. Clin Immunol Immunopathol (1980) 1.09
Neutrophil degranulation. Contemp Top Immunobiol (1984) 1.09
Effect of steroids on lysosomes. Transplant Proc (1975) 1.08
Synexin-like proteins from human polymorphonuclear leukocytes. Identification and characterization of granule-aggregating and membrane-fusing activities. J Biol Chem (1987) 1.08
Evidence of a role for mesothelial cell-derived interleukin 8 in the pathogenesis of asbestos-induced pleurisy in rabbits. J Clin Invest (1992) 1.07
Polymorphonuclear Leukocyte lysosomes and immune tissue injury. Prog Allergy (1976) 1.07
C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology (1987) 1.06
The C5a receptor of neutrophils and macrophages. Agents Actions Suppl (1983) 1.05
The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J Biol Chem (1996) 1.05
Generation of a chemotactic lipid from a arachidonic acid by exposure to a superoxide-generating system. Inflammation (1980) 1.04
Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med (1971) 1.03
Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J Immunol (1990) 1.03
A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem (2000) 1.03
A novel dioxygenation product of arachidonic acid possesses potent chemotactic activity for human polymorphonuclear leukocytes. J Biol Chem (1983) 1.02
Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem (1998) 1.02
Bacterial-lipopolysaccharide-induced release of lactoferrin from human polymorphonuclear leukocytes: role of monocyte-derived tumor necrosis factor alpha. Infect Immun (1987) 1.02
Complement (C5)-derived chemotactic activity accounts for accumulation of polymorphonuclear leukocytes in cerebrospinal fluid of rabbits with pneumococcal meningitis. Infect Immun (1984) 1.02
Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg (1986) 1.01
Leukocyte transfusions: role of leukocyte alloantibodies in determining transfusion response. Transfusion (1971) 1.01
Potentiation of the primary humoral immune response in vitro by C5a anaphylatoxin. J Immunol (1982) 1.01
Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide ("cochemotaxin") in normal serum and plasma. J Immunol (1981) 1.01
Prostaglandins, thromboxanes, and polymorphonuclear leukocytes: mediation and modulation of inflammation. Inflammation (1977) 1.00
Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur J Pharmacol (2000) 0.99
Infections and hypocomplementemia. Annu Rev Med (1983) 0.97
The secretory code of the neutrophil. J Reticuloendothel Soc (1979) 0.97
Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. N Engl J Med (1981) 0.97
Chemotactic activity of C5ades Arg: evidence of a requirement for an anionic peptide 'helper factor' and inhibition by a cationic protein in serum from patients with systemic lupus erythematosus. Mol Immunol (1980) 0.97
Receptor for activated C-kinase (RACK-1), a WD motif-containing protein, specifically associates with the human type I IFN receptor. J Immunol (2000) 0.96
Evidence of complement catabolism in acute pancreatitis. Am J Med Sci (1978) 0.94
A derivative of wheat germ agglutinin specifically inhibits formyl-peptide-induced polymorphonuclear leukocyte chemotaxis by blocking re-expression (or recycling) of receptors. J Immunol (1986) 0.94
Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and formyl-methionyl-leucyl-phenylalanine on rabbit polymorphonuclear leukocytes. J Immunol (1986) 0.93
Effect of bile on cyclosporine absorption in dogs. Res Commun Chem Pathol Pharmacol (1986) 0.93
Effect of high-dose methylprednisolone infusion on polymorphonuclear leukocyte function in patients with systemic lupus erythematosus. Arthritis Rheum (1981) 0.93
Interleukin-1beta induction of the chemokine RANTES promoter in the human astrocytoma line CH235 requires both constitutive and inducible transcription factors. J Neuroimmunol (2000) 0.92